GlaxoSmithKline Licenses Out Migraine Drug After Italian Antitrust Probe
MILAN (AFX) - Italy's antitrust authority said GlaxoSmithKline PLC has agreed to licence rights to its migraine drug Sumatriptan Succinato to the chemical firm FIS, so FIS can produce a generic migraine drug. The licensing by Glaxo removes the threat of antitrust fines after the authority found during an investigation that Glaxo had abused its dominant position in the pharmaceutical market.